NEWTON CHARLES W. (Chief Financial Officer) sold 3.0% of their position (267.00 shares) of LYELL IMMUNOPHARMA, INC. on the open market
Open‑market sale worth $2.8K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 8/13/2025ACC: 0001415889-25-021691
Officer· Chief Financial Officer
Since Jun 2021
-267.00
Net shares
Net seller
$2.8K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
267.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−131.00
Price / share
$10.53
Trade value
$1.38K
% of position
1.5%
8/11/2025
9.03K→8.89K
Common Stock
Direct
Shares
−136.00
Price / share
$10.34
Trade value
$1.41K
% of position
1.5%
8/12/2025
8.89K→8.76K
Total
Net shares
−267.00
Net value
-$2.78K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/11/2025 | S · Sale | −131.00 | $10.53 | $1.38K | 1.5% | 9.03K | 8.89K |
| Common Stock Direct | 8/12/2025 | S · Sale | −136.00 | $10.34 | $1.41K | 1.5% | 8.89K | 8.76K |
| Total | −267.00 | -$2.78K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned10K
Total
10K indirect10K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 10K | Indirect |
| Total | 10K | 10K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported